Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Nalbuphine Allergy × Morphine × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Neoplasms 19 Pain 17 Cancer Pain 16 Pain, Postoperative 9 Chronic Pain 7 Agnosia 5 Colonic Neoplasms 4 Breast Neoplasms 4 Neoplasm Metastasis 3 Multiple Myeloma 3 Mucositis 3 Lymphoma, Follicular 3 Lymphoma 3 Lung Neoplasms 3 Leukemia, Myeloid, Acute 3 Leukemia, Biphenotypic, Acute 3 Leukemia 3 Colorectal Neoplasms 3 Wounds and Injuries 2 Waldenstrom Macroglobulinemia 2 Thrombocythemia, Essential 2 Supratentorial Neoplasms 2 Sezary Syndrome 2 Primary Myelofibrosis 2 Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2 Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 Precancerous Conditions 2 Polycythemia Vera 2 Pdgfra-Associated Chronic Eosinophilic Leukemia 2 Pancreatic Neoplasms 2

Interventions

Nalbuphine 1 Morphine 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05073744 2022-12-29

Nalbuphine Versus Morphine for Perioperative Tumor Ablation

Zhongda Hospital

Phase 4 Unknown

Nalbuphine Allergy

Data powered by HemOnc (CC BY 4.0) Colophon ⚡